Live Breaking News & Updates on University Hospital Of Salamanca

Stay updated with breaking news from University hospital of salamanca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Robots and AI: The Future of Cell and Gene Therapy Manufacturing

Robots and AI: The Future of Cell and Gene Therapy Manufacturing
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United States , Castillay Leóp , Fermin Sanchez Guijo , European Society For Blood , University Hospital Of Salamanca , European Committee , International Society , Gene Therapy , European Society , Marrow Transplantation , University Hospital ,

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma. ....

Castillay Leóp , Maria Victoria Mateos , University Hospital Of Salamanca , University Hospital , Multiple Myeloma , Plasma Cell Myeloma , Proteasome Inhibitor , Biologic Therapy , Anemia Anaemia , Monoclonal Antibody ,

PFS With Venetoclax No Better Than With Pomalidomide for t(11;14) MM

Venetoclax plus dexamethasone did not improve PFS over pomalidomide plus dexamethasone in t(11;14)-positive relapsed/refractory MM. ....

Castillay Leóp , Maria Victoria Mateos , University Hospital Of Salamanca , International Myeloma Society Annual Meeting , International Myeloma Working Group , University Hospital ,

PFS With Venetoclax No Better Than With Pomalidomide for t(11;14) MM

Venetoclax plus dexamethasone did not improve PFS over pomalidomide plus dexamethasone in t(11;14)-positive relapsed/refractory MM. ....

Castillay Leóp , Maria Victoria Mateos , University Hospital Of Salamanca , International Myeloma Society Annual Meeting , International Myeloma Working Group , University Hospital ,

Talquetamab Wins Approval in Europe for Relapsed/Refractory Myeloma

The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy. ....

Edmond Chan , Maria Victoria Mateos , European Commission , University Hospital Of Salamanca , Victoria Mateos , University Hospital , Multiple Myeloma ,